Saturday 17 October 2026
Export UNBX’s income statement to Excel — free account
UNITY Biotechnology, Inc.
UNBX Healthcare Biotechnology
UNITY Biotechnology, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $236,000.00. In the quarter to March 2025, EPS fell 26.5% and free cash flow fell 23.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.06
0.00
0.00%
Follow UNBX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Trend | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 103.30 | 56.10 | 27.20 | 12.30 | 2.09 | 1.46 | 0.94 |
Analyst estimates 2025–2027 Powerpack |
|||
| High | — | — | — | 245.60 | 168.70 | 154.40 | 97.80 | 19.11 | 5.72 | 2.02 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 106 | 98 | 61 | 65 | 32 | 19 | 16 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.01 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 1 | — | — | — | 5 | 0 | — | — | ||||
| Gross margin, % | — | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | — | — | |||||
| EBT | — | (30) | (45) | (76) | (82) | (94) | (61) | (44) | (40) | (26) | |||||
| EBT margin, % | — | 0.00 | (3,231.26) | 0.00 | 0.00 | 0.00 | (1,269.34) | (18,842.80) | 0.00 | 0.00 | |||||
| Net income | — | (30) | (45) | (76) | (82) | (94) | (61) | (44) | (40) | (26) | |||||
| Depreciation | — | 0 | 1 | 1 | 2 | 7 | 5 | 3 | 6 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 4.32 | 0.00 | 0.00 | 0.00 | 0.86 | 0.02 | 0.00 | 0.00 | ||||
| Earnings | — | (114.17) | (139.64) | (27.00) | (18.80) | (18.40) | (10.90) | (4.68) | (2.70) | (1.54) | |||||
| Cash flow | — | (61.58) | (119.94) | (20.03) | (16.60) | (15.40) | (8.07) | (5.52) | (2.51) | (1.24) | |||||
| Capex | — | (8.43) | (5.28) | (0.45) | (0.36) | (0.13) | (0.03) | 0.03 | 0.01 | 0.00 | |||||
| Free cash flow | — | (70.00) | (125.23) | (20.48) | (16.96) | (15.53) | (8.11) | (5.49) | (2.50) | (1.24) | |||||
| Book value | — | 0.00 | 284.06 | 56.84 | 27.67 | 16.30 | 10.67 | 5.91 | 1.92 | 0.39 | |||||
| Shares, m | — | 0 | 0 | 3 | 4 | 5 | 6 | 9 | 15 | 17 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | — | — | — | 0.00 | 0.00 | — | — | ||||
| P/S | — | — | 0.00 | — | — | — | 0.00 | 0.00 | — | — | |||||
| P/B | — | — | 0.00 | — | — | — | 1.37 | 0.50 | — | — | |||||
| EV/Sales | — | — | 0.00 | — | — | — | 0.00 | 0.00 | — | — | |||||
| EV/FCF | — | — | 1.75 | — | — | — | (0.33) | 0.89 | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (16) | (38) | (57) | (72) | (78) | (45) | (52) | (37) | (21) | ||||
| Capex | — | (2) | (2) | (1) | (2) | (1) | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | (19) | (40) | (58) | (74) | (79) | (45) | (52) | (37) | (21) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 90 | 81 | 156 | 112 | 86 | 74 | 77 | 39 | 15 | ||||
| Total debt | — | — | 0 | 0 | 0 | 29 | 21 | 20 | — | — | |||||
| Net debt | — | (89) | (86) | (171) | (122) | (69) | (67) | (74) | (43) | (23) | |||||
| Shareholders’ equity | — | — | 91 | 161 | 121 | 83 | 60 | 56 | 28 | 6 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (30.55) | (87.54) | (53.92) | (49.42) | (61.03) | (43.22) | (35.71) | (41.95) | (50.29) | ||||
| ROIC | — | 0.00 | (628.56) | 0.00 | 0.00 | (413.16) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | 48.94 | 71.77 | (196.95) | (58.41) | (92.19) | (85.26) | (76.90) | (94.36) | (148.97) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Jun 2022
Charts ten years each
UNITY Biotechnology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ERNA Ernexa Therapeutics Inc. | $3.5M | — (loss-making) | — (loss-making) | −94.12% (below 0%: shrinking) | n/m | −64.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PPCB Propanc Biopharma Inc | $3.5M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | Compare |
| CVKD Cadrenal Therapeutics, Inc. | $3.5M | — (loss-making) | — | — | n/m | +26.24% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IOBTQ IO Biotech, Inc. | $3.5M | — (loss-making) | — | — | n/m | +11.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| UNBX UNITY Biotechnology, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | −23.10% (below 0%: shrinking) | 0.00% | 0.00% | |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.3M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.2M | — (loss-making) | — (loss-making) | −100.78% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $3.4M | — | — | −94.12% | — | −22.26% | 50.00% | 0.00% |
UNITY Biotechnology, Inc. (UNBX) key facts
- UNITY Biotechnology, Inc. (UNBX) is a Biotechnology company in the Healthcare sector.
- UNITY Biotechnology, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $236,000.00.
- As of October 14, 2025, UNBX traded at $0.06, a market capitalization of $3.4 million.
- Return on equity was −149.0% and debt-to-equity 0.00.
- Its Altman Z-score is −5.56 (distress zone) for fiscal 2022.